MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Biogen Inc.

< Previous 1 2 3 4 Next >
News headline image
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen to Realign Resources for Alzheimer's Disease Franchise
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB SAGE
News headline image
Biogen Appoints Monish Patolawala to its Board of Directors
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Completes Acquisition of Reata Pharmaceuticals
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB RETA
News headline image
LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Appoints Jane Grogan as Head of Research
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen to Acquire Reata Pharmaceuticals
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB RETA
News headline image
Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB IONS
News headline image
Biogen Announces Changes to Its Board of Directors
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Appoints Adam Keeney as Head of Corporate Development
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story